A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
- Conditions
- Non-Small Cell Lung Cancer
- Registration Number
- NCT00085826
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study is to determine if Aptosyn, when given in combination with Taxotere, will result in prolonged survival when compared to Taxotere alone.
This study will also help determine tumor response rates, and the safety profile of Aptosyn in combination with Taxotere.
This study has been completed and a publication is pending.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Not specified
- Target Recruitment
- 600
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (96)
Birmingham Hematology Oncology Associates
🇺🇸Birmingham, Alabama, United States
Birmingham Hematology and Oncology Associates, LLC
🇺🇸Birmingham, Alabama, United States
Northern Arizona Hematology and Oncology Associates
🇺🇸Flagstaff, Arizona, United States
Hematology & Oncology Associates
🇺🇸Phoenix, Arizona, United States
Northern Arizona Hematology & Oncology Associates
🇺🇸Sedona, Arizona, United States
Arizona Clinical Research Center
🇺🇸Tucson, Arizona, United States
Arkansas Oncology Associates, PA
🇺🇸Little Rock, Arkansas, United States
Pacific Coast Hematology/Oncology Medical Group, Inc.
🇺🇸Fountain Valley, California, United States
California Cancer Care, Inc.
🇺🇸Greenbrae, California, United States
Sharp Clinical Oncology Research
🇺🇸San Diego, California, United States
Scroll for more (86 remaining)Birmingham Hematology Oncology Associates🇺🇸Birmingham, Alabama, United States